Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence

Translational Oncology

Volumn 3, Issue 6, 2010, Pages 362-372

  Rasmussen, John C ^a,c   Tan, I Chih ^a,c   Marshall, Milton V ^a,c   Adams, Kristen E ^a,c   Kwon, Sunkuk ^a,c   Fife, Caroline E ^a,b   Maus, Erik A ^a,b   Smith, Latisha A ^a,b   Covington, Kyle R ^c   Sevick Muraca, Eva M ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOCYANINE GREEN;

ADULT; ARM; ARTICLE; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IMAGING; HUMAN; LEG; LYMPH VESSEL; LYMPHATIC SYSTEM; LYMPHEDEMA; MALE; NEAR INFRARED FLUORESCENCE IMAGING; OUTCOME ASSESSMENT; VELOCITY;

EID: 78650400912     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10190     Document Type: Article

References (30)

1. Swartz MA (2001). The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1-2), 3-20.
2. Sakorafas GH, Peros G, Cataliotti L, and Vlastos G (2006). Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 15(3), 153-165.
3. Farncombe M, Daniels G, and Cross L (1994). Lymphedema-the seemingly forgotten complication. J Pain Symptom Manage 9(4), 269-276.
4. Rockson SG (2001). Lymphedema. Am J Med 110(4), 288-295.
5. Ridner SH (2006). Pretreatment lymphedema education and identified educational resources in breast cancer patients. Patient Educ Couns 61(1), 72-79.
6. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C,Horgan K, BundredN,Monypenny I, et al. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9), 599-609.
7. Armer JM (2005). The problem of post-breast cancer lymphedema: impact and measurement issues. Cancer Invest 23(1), 76-83.
8. de Vries M, Vonkeman WG, van Ginkel RJ, and Hoekstra HJ (2006). Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol 32(7), 785-789.
9. Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ, and Ferrell RE (2008). HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 6(2), 65-68.
10. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL,McTigue MA, Alitalo K, and Finegold DN (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25(2), 153-159.
11. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, and Vikkula M (2003). Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedematelangiectasia. Am J Hum Genet 72(6), 1470-1478.
12. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, and Glover TW (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67(6), 1382-1388.
13. Brice G, Mansour S, Bell R, Collin JR, Child AH, Brady AF, Sarfarazi M, Burnand KG, Jeffery S, Mortimer P, et al. (2002). Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 39(7), 478-483.
14. Kriederman BM, Myloyde TL, Witte MH, Dagenais SL, Witte CL, Rennels M, Bernas MJ, Lynch MT, Erickson RP, Caulder MS, et al. (2003). FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedemadistichiasis syndrome. Hum Mol Genet 12(10), 1179-1185.
15. Kume T, Jiang H, Topczewska JM, and Hogan BL (2001). The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev 15(18), 2470-2482.
16. Sharma R, Wendt JA, Rasmussen JC, Adams KE, Marshall MV, and Sevick-Muraca EM (2008). New horizons for imaging lymphatic function. Ann N Y Acad Sci 1131, 13-36.
17. Szuba A and Rockson SG (1998). Lymphedema: classification, diagnosis and therapy. Vasc Med 3(2), 145-156.
18. Lucarelli RT, Ogawa M, Kosaka N, Turkbey B, Kobayashi H, and Choyke PL (2009). New approaches to lymphatic imaging. Lymphat Res Biol 7(4), 205-214.
19. Marshall MV, Rasmussen JC, Tan I-C, Aldrich MB, Adams KE, Wang X, Fife CE, Maus EA, Smith LA, and Sevick-Muraca EM (2010). Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. Open Surg Oncol J 2, 12-25.
20. Rasmussen JC, Tan IC, Marshall MV, Fife CE, and Sevick-Muraca EM (2009). Lymphatic imaging in humans with near-infrared fluorescence. CurrOpin Biotechnol 20(1), 74-82.
21. Unno N, Nishiyama M, Suzuki M, Yamamoto N, Inuzuka K, Sagara D, Tanaka H, and Konno H (2008). Quantitative lymph imaging for assessment of lymph function using indocyanine green fluorescence lymphography. Eur J Vasc Endovasc Surg 36(2), 230-236.
22. Unno N, Inuzuka K, Suzuki M, Yamamoto N, Sagara D, Nishiyama M, and Konno H (2007). Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema. J Vasc Surg 45(5), 1016-1021.
23. Suzuki M, Unno N, Yamamoto N, Nishiyama M, Sagara D, Tanaka H, Mano Y, and Konno H (2009). Impaired lymphatic function recovered after great saphenous vein stripping in patients with varicose vein: venodynamic and lymphodynamic results. J Vasc Surg 50(5), 1085-1091.
24. Sevick-Muraca EM, Sharma R, Rasmussen JC, Marshall MV, Wendt JA, Pham HQ, Bonefas E, Houston JP, Sampath L, Adams KE, et al. (2008). Imaging of lymph flow in breast cancer patients after microdose administration of a nearinfrared fluorophore: feasibility study. Radiology 246(3), 734-741.
25. Desmettre T, Devoisselle JM, and Mordon S (2000). Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv Ophthalmol 45(1), 15-27.
26. Team RDC (2008). R: A Language and Environment for Statistical Computing. (2.8.1 ed.). R Foundation for Statistical Computing, Vienna, Austria.
27. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, et al. (2001). A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 98(22), 12677-12682.
28. Zawieja DC, Davis KL, Schuster R, Hinds WM, and Granger HJ (1993). Distribution, propagation, and coordination of contractile activity in lymphatics. Am J Physiol Heart Circ Physiol 264(4), H1283-H1291.
29. Guidance for Industry, Investigators, and Reviewers (2006). Exploratory IND Studies. U.S. Department of Health and Human Services, Food and Drug Administration CDER, Rockville, MD.
30. Kwon S and Sevick-Muraca EM (2010). Functional lymphatic imaging in tumorbearing mice. J Immunol Methods 360(1-2), 167-172.